Cellectar Shares Edge Higher Following Investor Update Release

Cellectar Biosciences’ stock registered modest gains in Monday’s trading session, advancing 1.92% to reach $5.30. This upward movement coincided with the company’s release of its latest corporate presentation materials.

The biopharmaceutical firm published its updated investor presentation on Sunday, providing market participants with fresh insights into its strategic initiatives and developmental pipeline progress. The document outlines the company’s current direction and recent achievements across its oncology-focused programs.

Upcoming Conference Participation Highlights Activity

Market observers are noting Cellectar’s packed schedule of industry engagements through the remainder of September 2025:

• September 24, 2025: Participation in the “Targeted Radiopharmaceuticals Supply Chain and Manufacturing” conference
• September 25-28, 2025: Attendance at the AACR special conference on pediatric cancers
• September... Read more...